OPK

$1.57+$0.01 (+0.64%)live

Compare

Change$-2.25

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held · Bookmarked

0 · 0

portfolios · users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$1.2B

746M shares

52-week range

$0.98 – $1.73

79% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

P/S (TTM)

2.0

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$570M	-4.7%	$-0.22	$-0.24–$-0.19	—	4
2027	$589M	+3.3%	$-0.27	$-0.29–$-0.22	—	4
2028	$606M	+2.9%	$-0.24	$-0.28–$-0.21	—	2
2029	$651M	+7.5%	$-0.20	$-0.21–$-0.20	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-27	$-0.08	$-0.01	+87.5%
2026-04-28	$-0.07	$-0.07	+0.0%
2026-02-26	$-0.07	$-0.04	+42.9%
2025-10-29	$-0.02	$0.03	+250.0%
2025-07-31	$-0.12	$-0.19	-58.3%
2025-04-30	$-0.06	$-0.10	-66.7%
2025-02-27	$-0.08	$0.01	+112.5%
2024-11-07	$-0.10

DCF fair valuemodel estimate

Intrinsic value

$0.18

Price

$1.57

Implied downside

-88%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
OPKOPKO Health, Inc.	$1.57	+0.64%	$1.2B	—
CTEVClaritev Corporation	$35.54	-2.47%	$606M	—
DNTHDianthus Therapeutics, Inc.	$104.77	-2.71%	$5.9B	—
LFMDLifeMD, Inc.	$3.40	-1.16%	$164M	—
NKTRNektar Therapeutics	$66.64	-2.72%

Opko Health Inc.

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

www.opko.com

Employees: 2,275
IPO / List date: Nov 2, 1995
HQ: MIAMI, FL

Held by traders on TradeandTell

No one on the platform currently holds OPK.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	109,543	$124.9K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded OPK yet.

$OPK chatter on StockTwits

tymtested@tymtestedBullish9m
$OPK Frost still wants to make money!!
View on StockTwits ↗
G.@tradertrash9h
$OPK Or...are they building up cash for the new owners 🤔, ill be looking for the last of the labs to be sold next, just my thoughts and they are worth nothing
View on StockTwits ↗
tymtested@tymtestedBullish22h
$OPK finally somebody is noticing
View on StockTwits ↗
G.@tradertrashBearish1d
$OPK cashing in royalties early for more cash to burn is always a good sign 😱 so toxic imo
View on StockTwits ↗
Gassbagger54 Gassbagger54@Gasbagger2d
$OPK Opposition to Teva chairman's jet expenses. Some things never change. There is Nobody to stop Frost ,since he calls all the shots at Opko.
View on StockTwits ↗
tymtested@tymtested3d
$OPK on equivalent daily average, opko buys back 150,000 shares or about 6% of the stock traded. Even more impactful when considering the float is about 50% of outstanding shares.
View on StockTwits ↗
Gassbagger54 Gassbagger54@Gasbagger3d
$OPK Speaking at the Wells Fargo Healthcare Conference, President and Vice Chairman Elias Zerhouni said,a GLP-1/glucagon candidate in Phase I development.**OPK-8801001**,is at the investigational new drug stage and expects to enter clinical trials in the following month.A **CAR-T program,** a first clinical trial is expected at the end of the year or early next year.MDX-2001,with potential results expected early next year.OPKO expects Merck to make a decision on how to proceed in the near term, he said.He added that OPKO expects to pursue additional partnerships because it does not intend to independently fund every program through later stages. In every statement Zerhouni made he said EXPECTS. That is not definite. So it seems everything has been at a standstill for quite sometime . So what has 35 MILLION in R&D every quarter being spent on ?
View on StockTwits ↗
tymtested@tymtested3d
$OPK OPKO’s utilization of nondilutive financing is a good indication they believe stock price appreciation is near and frost didn’t want to dilute it. Also ,opko may want to run up the price fairly soon,(after they buyback) to use higher priced shares to buy COCP.
View on StockTwits ↗
G.@tradertrash4d
$OPK always tomorrow... for some reason 🙄 they never can deliver today❓ ray & hgh are successful, it's just sh never get to share in that success, but u can bet they never miss a raise or bonus or stock option, for a complete failure to sh, it's been years ive heard that tomorrow bs, they just keep funding, without showing any return for sh, gets old, same old sh*t, rinse & repeat
View on StockTwits ↗
tymtested@tymtestedBullish4d
$OPK opko will retain 100% of its royalties on mazdutide once LLY launches mazdutide in other countries outside of china. HUGE coming opportunity!
View on StockTwits ↗
Gassbagger54 Gassbagger54@Gasbagger4d
$OPK Everything Opko has done has been a failure for Shareholders,but yet ,Frost and Friends keep reaping big pay days. From all of his self serving investments ,Cocp,Entx ,Vbiv,Shareholders never received ONE SHARE of anything. Frost now wants you to believe in ModeX as all the cash is disappearing.
View on StockTwits ↗
August Allegri@Sierradude4d
$OPK 12.5 mil a year? At that rate they can pay their Israeli tax bill in 20 years.... don't piss on my back and tell me its raining.....
View on StockTwits ↗
tymtested@tymtestedBullish4d
$OPK i just hope opko can complete the stock buyback at these low prices.
View on StockTwits ↗
tymtested@tymtestedBullish4d
$OPK if opko were to announce that bioref labs were generating $12.5M earns annually the stock would probably explode!!whats the difference?!?
View on StockTwits ↗
tymtested@tymtestedBullish4d
$OPK CFO stated the $125M deal based on mazdutide royalties were equivalent to ten years of royalties! That's $12.5M annually of new and previously unrecognized ongoing and growing continuous earnings stream!! EARNINGS! at a 30 pe, that should have generated at least a share price increase of $.50 to $1.00!! so its going to take the market a moment to wake up!! mazdutide is growing fast!!
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.